Janus Henderson Group PLC Fate Therapeutics Inc Transaction History

Janus Henderson Group PLC

$188 Billion
Q4 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$2.02 - $5.04 $18 - $45	9 Added 0.03%	33,963 $72,000
Q2 2023 Aug 14, 2023	BUY	$4.76 - $6.59 $76 - $105	16 Added 0.05%	33,954 $161,000
Q1 2023 May 15, 2023	BUY	$4.24 - $11.12 $78,520 - $205,931	18,519 Added 120.11%	33,938 $193,000
Q4 2022 Feb 14, 2023	SELL	$9.86 - $23.83 $13.9 Million - $33.6 Million	-1,409,307 Reduced 98.92%	15,419 $155,000
Q3 2022 Nov 14, 2022	SELL	$21.04 - $36.06 $226,958 - $388,979	-10,787 Reduced 0.75%	1,424,726 $31.9 Million
Q2 2022 Aug 15, 2022	SELL	$17.78 - $42.39 $602,510 - $1.44 Million	-33,887 Reduced 2.31%	1,435,513 $35.6 Million
Q1 2022 May 16, 2022	SELL	$29.67 - $60.28 $2.17 Million - $4.41 Million	-73,204 Reduced 4.75%	1,469,400 $57 Million
Q4 2021 Feb 14, 2022	SELL	$47.84 - $64.34 $8.57 Million - $11.5 Million	-179,207 Reduced 10.41%	1,542,604 $90.3 Million
Q3 2021 Nov 16, 2021	SELL	$59.27 - $95.73 $6.17 Million - $9.97 Million	-104,173 Reduced 5.71%	1,721,811 $102 Million
Q2 2021 Aug 16, 2021	SELL	$67.25 - $92.52 $5.02 Million - $6.91 Million	-74,648 Reduced 3.93%	1,825,984 $158 Million
Q1 2021 May 17, 2021	SELL	$72.16 - $117.4 $46.5 Million - $75.7 Million	-644,936 Reduced 25.34%	1,900,632 $157 Million
Q4 2020 Feb 16, 2021	SELL	$38.09 - $100.95 $23.7 Million - $62.7 Million	-621,141 Reduced 19.61%	2,545,568 $231 Million
Q3 2020 Nov 16, 2020	SELL	$30.41 - $40.5 $15 Million - $20 Million	-492,685 Reduced 13.46%	3,166,709 $127 Million
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $7.35 Million - $12.8 Million	363,775 Added 11.04%	3,659,394 $126 Million
Q1 2020 May 14, 2020	BUY	$17.28 - $31.88 $56.8 Million - $105 Million	3,285,567 Added 32685.7%	3,295,619 $73.2 Million
Q4 2019 Feb 18, 2020	BUY	$13.39 - $20.73 $134,596 - $208,377	10,052 New	10,052 $197,000

Others Institutions Holding FATE

# of Institutions

167

Shares Held

101M

Call Options Held

41.3K

Put Options Held

15.9K

Redmile Group, LLC San Francisco, CA

12.9M
Shares

$13.3 Million
1.66% of portfolio
Vanguard Group Inc Valley Forge, PA

10.3M
Shares

$10.6 Million
0.0% of portfolio
Black Rock Inc. New York, NY

10.1M
Shares

$10.4 Million
0.0% of portfolio
Bellevue Group Ag Kuesnacht, V8

4.84M
Shares

$4.98 Million
0.16% of portfolio
Ken Griffin Citadel Advisors LLC | Chicago, Il

4.38M
Shares

$4.51 Million
0.0% of portfolio

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $99.9M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Account